Navigation Links
Medarex to Present at the UBS Global Life Sciences Conference
Date:9/17/2008

PRINCETON, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the UBS Global Life Sciences Conference at 4:30 p.m. Eastern Time on Monday, September 22, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at http://www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
2. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
3. Medarex Announces July 10 Live Webcast of R&D Day Event
4. Medarex to Present at the Jefferies Second Annual Healthcare Conference
5. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
6. Medarex to Present at the Bank of America 2008 Healthcare Conference
7. Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
9. Medarex to Receive Milestone Payment from Novo Nordisk
10. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Wash., Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ... brachytherapy and medical radioisotope applications for the treatment of ... today announced its financial results for the second quarter ... 31, 2015. --> ... quarter of fiscal 2016, which ended December 31, 2015, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated network ... two long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical ... Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will assume ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of ... on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert ...
(Date:2/10/2016)... ... February 10, 2016 , ... Global Stem ... agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate Global ... in the latest adipose and bone marrow therapies. , Through the new ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:1/27/2016)... Jan. 27, 2016  Rite Track, Inc. a leading ... West Chester, Ohio announced today the ... staff, based in Austin, Texas , ... to provide modifications, installations and technical support offerings for ... of PLUS, commented, "PLUS has provided world class service ...
Breaking Biology News(10 mins):